Abstract 205P
Background
The real-life experience of radium-223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC) in Asia is limited. In recent ERA223 study, the post-treatment osteoporotic fracture risk was unexpectedly found elevated when Ra223 was given in addition to abiraterone/prednisone in mCRPC, raising a concern of long-term bone safety with Ra223.
Methods
Hospital records of consecutive patients with mCRPC treated with Ra223 in 5 Hong Kong public hospitals from Nov 2015 to Oct 2018 were retrieved for the analysis of treatment pattern and clinical outcomes.
Results
We identified 42 men with bony mCRPC (median age: 73; 78.6% ECOG PS 0/1; 61.9% with bone pain; 50% lymphadenopathy; 14.3% visceral metastases) who received at least 1 dose of Ra233 (median 6, IRQ: 4-6). Median follow-up was 8.8 months. Ra223 was administered at a median of 3rd line setting (IQR: 2nd to 4th line) with 88.1% and 35.7% having prior androgen-receptor axis-targeted agents (ARTAs, i.e. abiraterone and enzalutamide) and docetaxel. Ra223 was used concomitantly with ARTAs and bone health agents at 23.8% and 45.2%, respectively. 64.5% of patients had subsequent therapies (16.7% chemotherapy; 42.9% ARTAs). Median time to PSA progression was 3.6 months (IQR: 3.5-4.5) and 48.6% (18/37) had 30% drop of ALP after 3rd injection. 26.9% (7/26) with bone pain requiring analgesics had symptomatic improvement but 15% had worsened pain. 66.7% of patients were free from symptomatic skeletal event (SSE), with 6-month and 1-year SSE rates being 11.9% and 26.2%. The median OS was 18.2 months (95%CI: 4.6-31.9) and was longer for patients who received >4 injections (27.7 vs 7.8 months, p = 0.015). The most common AEs were anemia (67%), fatigue (36%), bone pain (33%), thrombocytopenia (26%) and neutropenia (19%). Treatment discontinuation due to AEs was 8%. Non-osteoporotic fracture was seen in 3 patients (2 pathological and 1 traumatic).
Conclusions
Later line use of Ra223 was a common real-life practice. Efficacy and tolerability with Ra223 remains favorable in heavily-pretreated mCRPC, despite higher rate of hematological AE was seen. With nearly ¼ patients with concomitant ARTAs, osteoporotic fracture was not seen in this cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract